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and economic costs of ADHD are not well understood.
We sought to examine the impact of childhood ADHD
on caregivers’ work status and work productivity, and
patients’ health care use. METHODS: We conducted a
telephone survey of 154 caregivers of ADHD-diagnosed
children. Caregivers were identified from membership in
CHADD (Children and Adults with Attention-Deficit/
Hyperactivity Disorder). RESULTS: The mean number
of ADHD-diagnosed children per caregiver was 1.3
(range 1–4); 60% of children were in 6th grade or lower.
The reported mean number of prior year ADHD-related
visits to pediatricians, psychiatrists, psychologists, and
counselors was 2.0, 3.7, 2.9, and 6.6 visits, respectively.
In the 3 months prior to telephone survey, 18% of visits
were for unscheduled emergencies—63% of caregivers
reported some change in their work status as a result of
their child’s ADHD. Of these, 15% changed type of job,
46% reduced hours worked per week, and 11% stopped
working completely. During the 4 weeks prior to survey,
caregivers reported having lost an average of 0.8 days
from work and being 25% less productive, for an average
of 2.4 days attributed to their child’s ADHD—this is
equivalent to 39 days reduced caregiver productivity per
year. CONCLUSIONS: Childhood ADHD adversely af-
fects caregiver work status and work productivity.
ADHD also results in frequent unscheduled emergency
visits. Effective disease management of childhood ADHD
may ultimately mitigate substantial costs borne by em-
ployers and health care systems.
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OBJECTIVE: To examine the impact of clinical syn-
drome, type of medication and adherence on outpatient
utilization. METHODS: Baseline data predicted 6-month
outpatient utilization (n  985). Psychotherapy, clinic
visits (specimen collection), and total number of outpa-
tient visits were examined. Presence of medication (15
first-generation; 5 novel; both) was coded. Adherence re-
flected the 4-weeks prior to assessment. Clinical syn-
drome variables: deficit, hallucinations/delusions, and
disorganization. Negative binomial regression (adjusted
standard errors). RESULTS: Psychotherapy Visits: Posi-
tive effect observed for higher hallucinations/delusions
and use of both first- and second-generations. Clinic Vis-
its: The probability of visit was positively impacted by
higher disorganization, adherence, education less than
high school graduation, and CHAMPUS. Negative effect
noted for use of novel agents and having Medicare only.
Number of visits higher for those with higher disorgani-
zation. Total Outpatient Visits: Positive effect observed
for adherence at both periods and treatment with novel
agents alone or in combination with first-generation
agents. The clinical syndrome variables did not achieve
significance. CONCLUSIONS: The positive correlation
of medication adherence at both baseline and 6 months
with clinic visits and total visits is an important driver in
outpatient services utilization. The type of medication
positively impacts the number of visits, however, a nega-
tive association was observed between type of medication
and the probability of a clinic visit. It may be possible
that some persons using novel agents achieve improve-
ment through outpatient medication management (psy-
chotherapy visits) and may require less frequent clinic
visits (for specimen collection), suggesting that the favor-
able adverse event profile of second-generation agents
may promote community functioning. Positive symptoms
and disorganization drive the occurrence and number of
visits while the presence of deficit syndrome did not
achieve significance. These findings suggest that as treat-
ment costs vary by method, payers could benefit by as-
sessing clinical syndrome in order to estimate disease-
related payments accurately.
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OBJECTIVE: To examine the distribution of mental
health conditions comorbid to depression, especially anx-
iety, among patients treated for 1–6 months or 7–12
months with an SSRI. METHODS: The study comprised
a retrospective review of integrated medical and phar-
macy claims from a national managed care organization.
Continuously enrolled patients between the ages of 18
and 65 years were identified from the 1.9M claims under-
lying six IPA model plans for 1997–1998. Patients placed
on SSRI therapy following a 4 month period without
drugs were stratified according to underlying mental
health conditions and length of SSRI monotherapy. RE-
SULTS: Overall, between 47% and 52% of patients
placed on SSRI monotherapy had a history of depression;
an additional 5–12% had histories of anxiety without de-
pression. Greater proportions of patients for whom par-
oxetine was prescribed rather than either fluoxetine or
sertraline had anxiety comorbid to depression in the year
prior to initiating drug therapy(11.5%, 6.5%, 7.9%, re-
spectively)(Chi-square .001). The 40 or more percent of
patients without depression or anxiety in their histories—
12 months preceding initiation of drug therapy and
month of initiation—but treated with SSRIs often had di-
agnoses for other mental health conditions, specifically
neurotic disorders, affective psychoses, nondependent
abuse of drugs and adjustment reaction. These diagnoses
patterns persisted when patients were subset according to
persistence of therapy, i.e., SSRI therapy for greater or
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fewer than 6 months. CONCLUSIONS: These results
support the common belief that physicians differentially
prescribe SSRIs according to comorbid symptoms. Ob-
served differences in the prevalence of diagnoses across
SSRI therapies are consistent with differences in the range
of approved indications across drugs and preferential
prescribing of paroxetine for patients with comorbid
anxiety disorders.
PMH13
PRE-TREATMENT PATIENT DIFFERENCES: 
CHOICE OF DRUG THERAPY
WITHIN SCHIZOPHRENIA
Gibson PJ, Loosbrock DL
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: To examine pre-treatment differences in
characteristics of patients with schizophrenia treated
with olanzapine and risperidone, as reported in epidemi-
ologic studies. METHOD: All 15 non-randomized stud-
ies with olanzapine and risperidone cited in Medline or
presented at major conferences (APA, ECNP, WPA,
ISPOR) through 1999 were included. The direction, mag-
nitude, and statistical significance from all comparisons
of pre-treatment characteristics for schizophrenia pa-
tients initiating therapy on olanzapine or risperidone are
summarized. RESULTS: Several studies found olanzapine
patients were more likely to be younger and male. One of
six studies found younger mean age at onset, though
prior duration of illness results had no consistent direc-
tion. Other specific comparisons were included in only
one or two studies. History of hospital admission results
were mixed, though olanzapine patients had significantly
higher prior hospitalization costs in the one study with
that measure. Patients initiated on olanzapine were more
likely to have prior use of clozapine, depot antipsychot-
ics, and/or antidepressants, whereas patients initiated on
risperidone were more likely to have anticholinergic use
at therapy start. In one study, patients initiated on olan-
zapine had mean CGI scores and/or GAF scores indica-
tive of greater severity. CONCLUSIONS: When evalu-
ated, significant pre-treatment patient differences were
often found. Physicians may be choosing olanzapine ther-
apy for more complicated schizophrenic patients, indi-
cated by prior hospitalization cost, medication use, and
clinical assessment scores.
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OBJECTIVE: To determine how deficit syndrome relates
to patterns of antipsychotic drug use among persons with
schizophrenia receiving community-based care. METH-
ODS: Study participants were enrolled in the US Schizo-
phrenia Care and Assessment Program (SCAP). Data
were obtained from participants who completed the base-
line and 6-month assessments and were using antipsy-
chotic medications at baseline (n  1019). Presence of
deficit syndrome was assigned based on proxy methods
using clinical data (Kirkpatrick B., et al., 1989). Antipsy-
chotics were categorized as first-generation, second-gen-
eration, or other. Few participants received antipsychot-
ics in the ‘other’ category (2%) and were not included in
these analyses. Baseline characteristics and the presence
of deficit syndrome were used to predict two outcomes:
(1) the likelihood of receiving first-generation antipsy-
chotics at the initial assessment, and (2) the likelihood of
switching from one antipsychotic class to another be-
tween assessments. Covariates included demographic
(gender, race, age, marital status, education, insurance),
clinical (GAF, hallucinations/delusions, disorganization),
medication adherence, and site variables. Logistic regres-
sion was applied. RESULTS: Deficit syndrome was not
significantly related to use of a 1st-generation agent at
baseline. A positive association was found for African
Americans (.0004), lower hallucination/delusion scores
(.02), and several site indicators (.05) ( Orlando, Den-
ver, Baltimore, and San Diego). The probability of
switching antipsychotic classes between assessments was
significantly related to one site indicator (.01) (Orlando);
weak evidence (.08) of lower GAF scores being associ-
ated with a switch was observed. The presence of deficit
syndrome did not achieve significance in either model.
CONCLUSIONS: The deficit syndrome has been studied
extensively in its relation to neurological function and
course of illness. In the SCAP population of patients re-
ceiving community-based care at diverse settings, we do
not find a relation between deficit syndrome and two
measures of antipsychotic drug assignment. Further re-
search may include evaluation of the relationship be-
tween deficit syndrome and drug assignment patterns
over time.
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OBJECTIVES: The purpose of this study was to assess
the one-year direct schizophrenia-related treatment costs,
mental health care costs and total health care costs for
patients diagnosed with schizophrenia and initiating ther-
apy with either olanzapine or risperidone. METHODS: A
retrospective analysis of the integrated medical and phar-
macy claims of a large, geographically diverse, commer-
cially insured population was conducted. A previously
validated algorithm to identify schizophrenics was used
for patient selection. The confirmed schizophrenia pa-
